Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis

DANIEL WENDLING, HÉLÈNE LETHO-GYSELINCK, XAVIER GUILLOT and CLÉMENT PRATI
The Journal of Rheumatology March 2012, 39 (3) 657; DOI: https://doi.org/10.3899/jrheum.111166
DANIEL WENDLING
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dwendling@chu-besancon.fr
HÉLÈNE LETHO-GYSELINCK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XAVIER GUILLOT
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CLÉMENT PRATI
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

Tocilizumab (TCZ) is a humanized monoclonal antibody directed against the interleukin 6 (IL-6) receptor, approved in the treatment of rheumatoid arthritis (RA), with potential use in other inflammatory diseases1. We describe a case of psoriasis onset during TCZ treatment in a patient with RA.

A white woman, born in 1955, for 20 years had erosive RA, negative for anticitrullinated protein antibodies. Her condition did not respond to several disease-modifying antirheumatic drugs (hydroxychloroquine, methotrexate, leflunomide) or to 2 tumor necrosis factor-α (TNF-α) blockers (etanercept, adalimumab). TCZ was then tried: 8 mg/kg/infusion in monotherapy, and later with 5 mg/day prednisone. After the third infusion (9 weeks of exposure to TCZ), she developed for the first time a psoriasis eruption on the left leg (Figure 1) and left elbow. The diagnosis was confirmed by a dermatologist and treated topically, without discontinuing TCZ. At the onset of psoriasis lesions, the RA responded to the treatment (28-joint Disease Activity Score 5.12 to 3.49; erythrocyte sedimentation rate 15 mm/h; C-reactive protein 1.5 mg/l).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Erythematous squamous lesions of the leg.

This case may illustrate a new kind of unexpected event in a patient whose arthritis is controlled by TCZ. Similar cases have been reported2, with exacerbation of preexisting psoriasis within 2 weeks after the first infusion of TCZ. Ogata, et al3 reported 2 cases of psoriatic arthritis treated with TCZ over 6 months without improvement in arthritis and skin lesions. Conversely, Brulhart, et al4 described a complete resolution of skin psoriasis in a patient treated with TCZ for severe ankylosing spondylitis associated with Crohn’s disease.

Increased production of IL-6 and upregulation of transcription factor STAT3 induced by IL-6 have been shown in psoriasis5, and plasma IL-6 levels seem to reflect psoriasis activity and treatment response6. Under these circumstances, onset or exacerbation of psoriasis is unexpected.

This kind of new onset or reactivation of psoriasis under biologic therapy for rheumatologic indications has been reported with TNF blockers7, rituximab8, and abatacept9.

In the few cases reported, psoriasis with TCZ is mild and may be controlled with topical treatment, with continuation of IL-6 blockade if effective on joint and general disease symptoms.

REFERENCES

  1. 1.↵
    1. Pham T,
    2. Claudepierre P,
    3. Constantin A,
    4. de Bandt M,
    5. Fautrel B,
    6. Gossec L,
    7. et al.
    Tocilizumab: therapy and safety management. Joint Bone Spine 2010;77 Suppl 1:S3–100.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Laurent S,
    2. Le Parc JM,
    3. Clerici T,
    4. Bréban M,
    5. Mahé E
    . Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010;136:1364–5.
    OpenUrl
  3. 3.↵
    1. Ogata A,
    2. Umegaki N,
    3. Katayama I,
    4. Kumanogoh A,
    5. Tanaka T
    . Psoriatic arthritis in two patients with inadequate response to treatment with tocilizumab. Joint Bone Spine 2011 Sep 29 [E-pub ahead of print.]
  4. 4.↵
    1. Brulhart L,
    2. Nissen MJ,
    3. Chevallier P,
    4. Gabay C
    . Tocilizumab in a patient with ankylosing spondylitis and Crohn’s disease refractory to TNF antagonists. Joint Bone Spine 2010;77:625–6.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Grossman RM,
    2. Krueger J,
    3. Yourish D,
    4. Granelli-Piperno A,
    5. Murphy DP,
    6. May LT,
    7. et al.
    Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367–71.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Zalewska A,
    2. Glowacka E,
    3. Wyczolkowska J,
    4. Tchorzewski H,
    5. Narbutt J,
    6. Sysa-Jedrzejowska A
    . Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis. Mediators Inflamm 2006;2006:81767.
    OpenUrlPubMed
  7. 7.↵
    1. Wendling D,
    2. Balblanc JC,
    3. Briançon D,
    4. Brousse A,
    5. Lohse A,
    6. Deprez P,
    7. et al.
    Onset or exacerbation of cutaneous psoriasis during TNF-alpha antagonist therapy. Joint Bone Spine 2008;75:315–8.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Markatseli TE,
    2. Kaltsonoudis ES,
    3. Voulgari PV,
    4. Zioga A,
    5. Drosos AA
    . Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 2009;27:996–8.
    OpenUrlPubMed
  9. 9.↵
    1. Florent A,
    2. Albert C,
    3. Giacchero D,
    4. Roux C,
    5. Euller-Ziegler L
    . Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine 2010;77:626–7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 3
1 Mar 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis
DANIEL WENDLING, HÉLÈNE LETHO-GYSELINCK, XAVIER GUILLOT, CLÉMENT PRATI
The Journal of Rheumatology Mar 2012, 39 (3) 657; DOI: 10.3899/jrheum.111166

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis
DANIEL WENDLING, HÉLÈNE LETHO-GYSELINCK, XAVIER GUILLOT, CLÉMENT PRATI
The Journal of Rheumatology Mar 2012, 39 (3) 657; DOI: 10.3899/jrheum.111166
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Herpes Zoster Vaccine and Rheumatoid Arthritis
  • Seasonal Variations and Their Influence on Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Relapse
  • Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire